Microplastics and Misinformation: What Science Really Says
November 12, 2025
Brand Name :
Urispas, flavoxate
Synonyms :
Flavoxate, flavoxato
Class :
Antispasmodic agent,
Dosage Forms & StrengthsÂ
TabletÂ
100mgÂ
100 - 200
mg
Tablet
Orally 
every 6-8 hours
100-200mg orally every 6-8 hours
Dosage Forms & StrengthsÂ
TabletÂ
100mgÂ
<12 years: Safety and efficacy not established
>12 years:100-200mg orally every day for every 6-8 hours
may increase the constipating effect of anticholinergic agents
may diminish the therapeutic effects
may increase the anticholinergic effect
may increase the anti-cholinergic effect
may increase the constipating effect of anticholinergic agents
may increase the anti-cholinergic effect
may increase the anti-cholinergic effect
may increase the anti-cholinergic effect
may increase the anti-cholinergic effect
may increase the anti-cholinergic effect
may increase the anti-cholinergic effect
may increase the anti-cholinergic effect
may diminish the therapeutic effect
may increase the anti-cholinergic effect
may increase the constipating effect of anticholinergic agents
may increase the toxic effects of anti-cholinergic
may diminish the therapeutic effect
may diminish the therapeutic effect
may diminish the therapeutic effect
may diminish the therapeutic effect
may diminish the therapeutic effect
may increase the anti-cholinergic effect
may increase the anti-cholinergic effect
may increase the anti-cholinergic effect
may increase the anti-cholinergic effect
may increase the anti-cholinergic effect
may decrease the therapeutic effect
may decrease the therapeutic effect
may decrease the therapeutic effect
may decrease the therapeutic effect
may decrease the therapeutic effect
it may diminish the therapeutic efficacy when combined with castor oil
When flavoxate is used together with profenamine, this leads to enhanced risk or seriousness of adverse events
may decrease the cholinergic effect of cholinergic agents
the therapeutic activity of flavoxate may be decreased
Frequency defined:Â Â
Blurred visionÂ
DrowsinessÂ
DysuriaÂ
HeadacheÂ
Increased ocular tensionÂ
NervousnessÂ
TachycardiaÂ
VertigoÂ
Abdominal painÂ
ConfusionÂ
Disturbance in ocular accommodationÂ
Dry mouthÂ
EosinophiliaÂ
HyperpyrexiaÂ
NauseaÂ
PalpitationÂ
UrticariaÂ
VomitingÂ
Pregnancy consideration: BÂ
Lactation: Excretion of the drug in human breast milk is unknownÂ
Pregnancy category:Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.  Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this categoryÂ
Patient information leafletÂ
Generic Name: flavoxateÂ
Pronounced: flah-VOX-ateÂ
Why do we use flavoxate?Â
It is used to treat urinary tract infectionsÂ